ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.68
0.23%
US Tech 100
19,393.20
-0.05%
S&P 500
5,484.48
0.21%
US Dollar vs CAD
1.37227
0.06%
Bitcoin
64,827.50
-2.50%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. MIRA Pharmaceuticals Inc (MIRA)

  7. MIRA Pharmaceuticals Inc (MIRA) News

MIRA

MIRA Pharmaceuticals (MIRA)

MIRA Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MIRA
DateTimeSourceHeadlineSymbolCompany
06/10/20247:30AMPR Newswire (US)Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This YearNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/30/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/29/20247:45AMPR Newswire (US)Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled SubstanceNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/29/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/22/20244:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/21/20247:45AMPR Newswire (US)MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/20/20247:00AMPR Newswire (US)Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/13/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRAMIRA Pharmaceuticals Inc
04/02/20247:00AMPR Newswire (US)Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND SubmissionNASDAQ:MIRAMIRA Pharmaceuticals Inc
03/21/202410:04AMPR Newswire (US)MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific AdvisorNASDAQ:MIRAMIRA Pharmaceuticals Inc
03/07/20243:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
02/05/20247:30AMPR Newswire (US)MIRA Pharmaceuticals Provides Corporate UpdateNASDAQ:MIRAMIRA Pharmaceuticals Inc
01/17/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
12/27/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MIRAMIRA Pharmaceuticals Inc
12/27/20234:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
12/27/20234:27PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
12/18/20233:50PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MIRAMIRA Pharmaceuticals Inc
12/04/20237:00AMPR Newswire (US)MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence SimulationsNASDAQ:MIRAMIRA Pharmaceuticals Inc
12/01/20234:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/29/20237:00AMPR Newswire (US)MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%NASDAQ:MIRAMIRA Pharmaceuticals Inc
11/21/20239:42AMPR Newswire (US)MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/21/20239:09AMPR Newswire (US)MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1aNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/20/20233:18PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
11/20/20233:15PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/20/20237:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/20/20237:00AMPR Newswire (US)MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2NASDAQ:MIRAMIRA Pharmaceuticals Inc
09/18/20237:30AMPR Newswire (US)MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than PotNASDAQ:MIRAMIRA Pharmaceuticals Inc
09/05/20237:31AMPR Newswire (US)MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication EffortsNASDAQ:MIRAMIRA Pharmaceuticals Inc
08/31/20237:31AMPR Newswire (US)MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development SummitNASDAQ:MIRAMIRA Pharmaceuticals Inc
08/29/202310:39AMPR Newswire (US)MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIRA

Your Recent History

COIN
GUESSGBP
BIT
UB261R
UniCredit Bank
LSE
43QU
Jp Morgan. 24
AQEU
BNP
Danone
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved